Changing the Game - Aiming to Cure.

Xavier oversees Tr1X's Clinical Development team and is responsible for executing on the Company's clinical programs. Prior to Tr1X, Xavier served as head of clinical development across a series of biotechnology companies including Design Therapeutics, Strongbridge Biopharma and Boston Pharmaceuticals, where he was responsible for all aspects of clinical development from IND submission through BLA filings. Prior to his career in biotechnology, Xavier served in positions of increasing responsibility in immunological clinical development at BMS and Novo Nordisk. Xavier also spent six years at NIH researching the role of regulatory T cells in tolerance. Xavier holds an MD from the School of Medicine at the National University of Mexico and is a board certified rheumatologist.

Dr. Kathy High is an accomplished hematologist with a longstanding interest in gene therapy for genetic disease. Most recently, Dr. High served as the President, Therapeutics of AskBio, a subsidiary of Bayer AG, and as a member of AskBio’s board of directors. Previously, Dr. High co-founded Spark Therapeutics, Inc. and from September 2014 to December 2019, she served as its President and as a member of its board of directors and served as its Head of Research & Development from September 2017 to February 2020. Dr. High also serves as a director of Incyte Corporation and CRISPR Therapeutics. From 2004 to 2014, Dr. High was a Professor at the Perelman School of Medicine at the University of Pennsylvania, an Investigator at Howard Hughes Medical Institute and the Director of the Center for Cellular and Molecular Therapeutics at the Children’s Hospital of Philadelphia. She completed a five-year term from 2000 to 2005 on the U.S. Food and Drug Administration Advisory Committee on Cell, Tissue and Gene Therapies and is a past president of the American Society of Gene & Cell Therapy. Dr. High holds an A.B. in chemistry from Harvard University, an M.D. from the University of North Carolina School of Medicine, a business certification from the University of North Carolina Business School Management Institute for Hospital Administrators and an honorary M.A. from The University of Pennsylvania.

Fuad is an Associate Scientist at Tr1x in the Process Development team. He graduated from California State University, Northridge with a BS in Biology. He brings over 11 years of experience in biotechnology and gene therapy working for companies like Biolegend, Kite Pharma, Poseida therapeutics in process optimization and most recently at Fate Therapeutics where he was helping develop and characterize newly generated iPSC cell lines and across the manufacturing function for a variety of potential new therapies. His passion continues to drive his work and contribute to the field of biotechnology to improve patient outcomes.

Jennifer is an experienced Quality leader, with nearly 30 years experience in Biotech, Pharma, and Cell Therapy industries. She has held various leadership roles with increasing responsbilities and experienced in working in start-up and established company environments. Prior to joining Tr1X, she was with Instil Bio as the Site Quality Head responsible for leading the Clinical Manufacturing Quality organization. Some of her key contributions included building the Quality organization, establishment of the QMS, and supporting Technology Transfers, IND(a) submissions, and routine clinical manufacturing operations. Jennifer also worked at Teva Pharmaceutical as Site Quality Head and at Baxter/Takeda in roles with increasing responsibility throughout her almost 25 years tenure supporting commercial manufacturing operations. Jennifer holds a bachelors degree in Biological Sciences from University of California, Irvine (UCI).

Coming soon...

Steven is a Senior Research Associate on the Biology team at Tr1x. Prior to Tr1x, Steven has spent the last 4 years in the biotech industry working primarily in the gene editing and immuno-oncology arenas at Editas Medicine, Artisan Biotechnologies, and most recently at Fate Therapeutics as a part of the iPSC T Cell therapy team. Steven graduated from Emmanuel College in Boston, MA with a degree in Biochemistry. When not in lab he can be found getting up to anything and everything outdoors thanks to his New Hampshire upbringing.

Jan de Vries has more than 30 years of experience in drug discovery and development. Prior to serving as Tr1X's co-founder and inaugural CEO, he was the CEO of AIMM Therapeutics, a therapeutic antibody company which discovered Beyfortus® and licensed it to Medimmune/AstraZeneca. Prior to that Jan was a SVP at Novartis and global head of the Disease Area, Autoimmune-Inflammatory Diseases and Transplantation, where he led the discovery and early development of (amongst others): Elidel®, Cosentyx®, Gilenya®, Ilaris® and Maizent®. Jan holds a PhD in Immunology from the University of Amsterdam and did his postdoctoral studies in the field of tumor immunology with Dr John Mendelsohn at the University of California, San Diego.

Maria Grazia is the George D. Smith Professor in Stem Cell and Regenerative Medicine, Professor of Pediatrics and of Medicine, founder of the Center for Definitive and Curative Medicine, and former co-director of the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University. Dr. Roncarolo has spent her career translating discoveries in immune-mediated diseases and regenerative medicine into novel patient therapies. Dr. Roncarolo and her team were the first to discover T regulatory Type 1 cells in patients, and the first to develop curative treatments for ADA-SCID. A pediatric immunologist by training, she was instrumental in bringing novel cell and gene therapies to market including Strimvelis® and Libmeldy®. Dr Roncarolo is a co-founder of the gene-editing company Graphite Bio (NSDQ: GRPH), where she still serves as the Chair of the Scientific Advisory Board.

"Xavier is an immunologist and translational scientist with over 25 years of experience in Research & Development across an array of therapeutic areas including immune-inflammation, (immuno)-oncology and precision medicine. Prior to joining Tr1X, Xavier served as the Vice President Immunology at Personalis where he led the development of precision cancer therapies, and the integration of genomic, immunological and clinical data to enable precision oncology. Prior to that, he held positions of increasing responsibility in pharmaceutical and biotechnology companies including Ultragenyx, MedImmune, ARYx, Gryphon, Merck, and Chiron. Xavier has contributed to multiple successful global drug approvals including Proleukin®, Gardasil®, FluMist® quadrivalent, and Imfinzi®). He holds a PhD in Immunology and a PharmD from the Claude Bernard University in Lyon."

David has over a decade of experience founding and scaling companies at the intersection of healthcare and technology. Prior to Tr1X, David was Co-Founder and COO of Arine, a therapeutic optimization company he helped launch and scale to serve millions of patients across the US. Before that, he worked at Proteus Digital Health, one of the first techbio companies and the first in the field to obtain FDA approval for a digital medicine, Abilify MyCite®. Previously, David worked on various initiatives related to innovative healthcare payment models and the impact of the Affordable Care Act. David holds an undergraduate degree from Harvard and completed his graduate studies at the University of Cambridge.

James has 30 years of operational experience across a wide range of disciplines including research and development, manufacturing, quality operations, and marketing and sales. He most recently served as Vice President of Manufacturing at Sonoma Biotherapeutics where he created a technical operations team in support of developing cell therapies targeting autoimmune disorders. Prior to joining Sonoma, James led the clinical manufacturing division at the Fred Hutch Cancer Research Center where he had direct responsibility for the technical components of over 20 INDs and 9 DMFs involving both biologics and cell & gene therapy products. James has a Master’s in Business Administration from Rivier University and a BS in Microbiology from Michigan State University.

Max serves as Tr1X’s Director of Biology. Before joining Tr1X, Max’s work focused on cell engineering, gene editing, and the early development of off-the-shelf cell therapy assets, most recently as an Associate Director, Immuno-Oncology at Poseida Therapeutics. Max holds a PhD in Biology from the Humboldt University of Berlin.

Daryl is a Principal Scientist in Vectorology at Tr1X. He has done extensive molecular virology research in the HIV field, and previously served as a Senior Scientist at Sana Biotechnology identifying cellular factors restricting gene therapy. Daryl received a PhD in Molecular and Cellular Biology from the University of Washington.

Dr. Flavell is Sterling Professor of Immunobiology at Yale University School of Medicine, and an Investigator of the Howard Hughes Medical Institute. He received his B.Sc. (Honors) in 1967 and Ph.D. in 1970 in biochemistry from the University of Hull, England, and performed postdoctoral work in Amsterdam (1970-72) with Piet Borst and in Zurich (1972-73) with Charles Weissmann. Before accepting his current position in 1988, Dr. Flavell was first Assistant Professor (equivalent) at the University of Amsterdam (1974-79); then Head of the Laboratory of Gene Structure and Expression at the National Institute for Medical Research, Mill Hill, London (1979-82); and subsequently President and Chief Scientific Officer of Biogen Research Corporation, Cambridge, Massachusetts (1982-88). Dr. Flavell is a fellow of the Royal Society, a member of the National Academy of Sciences as well as the National Academy of Medicine. Dr. Flavell uses transgenic and gene-targeted mice to study Innate and Adaptive immunity, T cell tolerance and activation in immunity and autoimmunity,apoptosis, and regulation of T cell differentiation.

Dr. Vijay Kuchroo is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women’s Hospital, and Co-Director of the Center for Infection and Immunity, at the Brigham Research Institutes, Boston. He is also an associate member of the Broad Institute, and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. He is the founding Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital. His major research interests include autoimmune diseases—particularly the role of co-stimulation—the genetic basis of experimental autoimmune encephalomyelitis and multiple sclerosis, as well as cell surface molecules and regulatory factors that regulate the induction of T cell tolerance and dysfunction. His laboratory bred several transgenic mice that serve as animal models for human multiple sclerosis. The Kuchroo laboratory was also the first to describe the TIM family of genes, and identified Tim-3 as an inhibitory receptor expressed on T cells, which is now being exploited for cancer immunotherapy. He was first to describe the development of highly pathogenic Th17 cells, which have been shown to induce multiple different autoimmune diseases in humans. Dr. Kuchroo is the lead author on a paper describing the development of Th17, which is one of the most cited papers in the field of Immunology.

Dr. Luigi Naldini, is Professor of Cell and Tissue Biology and of Gene and Cell Therapy at the San Raffaele University School of Medicine and Scientific Director of the San Raffaele Telethon Institute for Gene Therapy (Milan, Italy). He has received his medical degree from the University of Turin (Italy) and his PhD from the University “La Sapienza” of Rome (Italy). For the past 25 years he has pioneered the development and the applications of lentiviral vectors for gene therapy, which have become one of the most widely used tools in biomedical research and, upon recently entering clinical testing, are providing a long-sought hope of cures for several currently untreatable and otherwise deadly human diseases. Throughout this time, he has continued to investigate new strategies to overcome the major hurdles to safe and effective gene transfer, bringing about innovative solutions that are not only being translated into new therapeutic strategies for genetic disease and cancer, but have also allowed novel insights into hematopoietic stem cell function, induction of immunological tolerance, and tumor angiogenesis. His work also contributed to advance the use of artificial nucleases for targeted genome editing in cell and gene therapy. He has published over 280 scientific papers.

Jie serves as Tr1X’s Director of Analytical Sciences. Jie has developed expertise on analytical development via working through different therapeutic fields, including siRNA therapeutics, monoclonal antibody therapies targeting cancer stem cells and immune check points, and cell therapies, most recently as a principal scientist as the head of analytical development at Cero Therapeutics. Jie holds a PhD in Biochemistry and Plant Physiology from the Chinese Academy of Sciences.

Vikas works as a Senior Scientist in Tr1X's Bioanalytical Development team. Previously Vikas worked with bispecific biologics targeting cancer neoantigens, studied regulatory T cell migration and stability and the role of microbiota in solid organ transplantation. He has experience working with in vivo mouse and non-human primate models. Vikas received his PhD in virology from Academia Sinica, Taipei, Taiwan and Bachelor's in veterinary medicine (DVM) from Pantnagar, India.

Molly is a Scientist II in Tr1x’s Biology team. Before joining Tr1x, Molly worked on assay development on regulatory T cells, gene editing, and cell line development. Molly received her PhD from Stanford’s Stem Cell Biology and Regenerative Medicine in the lab of Maria Grazia Roncarolo and her B.S. in Molecular, Cellular, Developmental Biology from UCLA.

Audrey is a Sr. Research Associate on the Biology team. Prior to working at Tr1X, Audrey worked in the biotech industry for 4 years across cancer drug development and early adenovirus research. She recieved her Bachelor's degree in Biology and Psychology from US Santa Cruz.

Chunyi is a Research Associate on the Biology team. Before joining Tr1X, Chunyi worked on cell based platforms focusing on immunotherapy. Chunyi obtained her B.S in Biochemistry and Cell Biology from UCSD.

Kevin is an Associate Scientist in Tr1X’s Process Development team. He brings over 7 years of experience spanning roles in research to technical operations across multiple drug modalities. Recently, Kevin’s work has focused on the optimization of production and manufacturing processes for therapeutic applications. Kevin is currently pursuing a master’s degree at San Diego State University and received his undergraduate degree from California State University, East Bay.

Michelle is a Research Associate in Tr1X's Vectorology department. Michelle brings her experience in cell culturing primary cells to Tr1X from her previous position at Crown Bioscience. She also helped with bat cochlea research during her time in undergrad at UC Merced where she graduated with a B.S. in Evolutionary and Ecological Biology.

Alex is a Research Associate II in Tr1X's Bioanalytical Developmental team. Alex has worked at the Genomics Institute of the Novartis Research Foundation in the Cancer Therapeutics Department and her most recent role was at Becton Dickinson working in the Hybridoma/Antibody Development group. She graduated from San Diego State University in 2020 with a degree in Cell and Molecular Biology and completed a CIRM fellowship and IMSD internship during her time at SDSU.

Coming soon...